Ipsen Dysport hits Phase III endpoints in episodic and chronic migraine
Ipsen has announced positive topline results from its two-part BEOND Phase III programme evaluating Dysport (abobotulinumtoxinA) for migraine prevention, with both the episodic (E-BEOND) and chronic (C-BEOND) trials meeting their primary endpoints. The primary endpoint in each study was the change from baseline in monthly migraine days at week 24, measured against placebo.
The E-BEOND result is of particular note: it is the first time any botulinum toxin has demonstrated statistically significant efficacy in episodic migraine in a Phase III setting. Chronic migraine has had an approved botulinum toxin option since onabotulinumtoxinA (Botox) received regulatory clearance for that indication in 2010, but episodic migraine has remained outside the class's proven reach. Together, the two trials enrol 1,510 patients across 120 centres, making BEOND one of the larger Phase III programmes in migraine prevention to report in recent years.
Ipsen said Dysport was well-tolerated across both studies and that the safety profile was consistent with the product's established use in other approved indications. No new or unexpected signals were identified. Full datasets, including responder rates and secondary endpoints, are expected to be presented at a future scientific congress.
Clinical and regulatory context
Christelle Huguet, EVP and Global Head of R&D at Ipsen, said the results "position Dysport as a potential first-in-class treatment for a broad migraine population." That positioning, while the company's own framing, does reflect a genuine clinical gap: episodic migraine, defined in E-BEOND as up to 14 headache days per month with at least six migraine days, represents a substantially larger patient population than chronic migraine. Approved preventive therapies for episodic migraine include oral agents such as topiramate and propranolol, as well as the more recently approved anti-CGRP monoclonal antibodies erenumab, fremanezumab and galcanezumab. A botulinum toxin approved in episodic migraine would represent a mechanistically distinct option.
Ipsen has not yet disclosed a regulatory filing timeline. The extension phase of both BEOND trials, in which all participants receive Dysport for two further treatment cycles, continues to week 48. Regulators at the FDA and EMA are likely to request longer-term data alongside the topline package before reviewing any new indication submission.
Market context
The migraine therapeutics market has broadened considerably since the approval of the first anti-CGRP therapies in 2018. Analysts estimate more than 1 billion people experience migraine globally, with roughly 14% of the world's population affected according to the Global Burden of Disease study cited by Ipsen. Despite the expansion of the anti-CGRP class, a meaningful share of patients either does not respond to or does not tolerate existing preventive options, sustaining demand for differentiated approaches.
Dysport already holds marketing authorisation in approximately 90 countries across its existing indications and carries more than 30 years of post-marketing experience. That established manufacturing and distribution infrastructure gives Ipsen a potential commercialisation advantage over newer entrants, should regulatory approval in migraine be secured. Whether payers will view a botulinum toxin injection regimen as cost-effective relative to oral generics or subcutaneous anti-CGRP therapies will be a key access question in every major market.